AXT, Inc. (AXTI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows mixed signals: improvements in gross margins and operating expenses are positive, but ongoing losses and cash depletion are concerning. The Q&A reveals potential growth in indium phosphide demand, but uncertainties in export licenses and permitting delays pose risks. The company's optimistic guidance and backlog could boost stock, but lack of clarity on license issues tempers this optimism. The absence of a market cap makes it hard to predict volatility, but overall, the sentiment is balanced, leading to a neutral stock price prediction.
Key Financial Performance
Revenue $18.0 million in Q2 2025, compared to $19.4 million in Q1 2025 and $27.9 million in Q2 2024. This represents a year-over-year decrease of approximately 35.5%, primarily due to slower export permit processing and sluggish demand in China.
Indium Phosphide Revenue $3.6 million in Q2 2025, driven by PON and data center applications in China. Growth in AI-related demand for indium phosphide substrates in China contributed positively.
Gallium Arsenide Revenue $6.2 million in Q2 2025. Growth in wireless business in China contributed positively, despite sluggish demand and slower export permit processing.
Germanium Substrates Revenue $1.5 million in Q2 2025, driven by satellite solar cell applications in China. However, the market remains price-sensitive, and export permits for sales outside China are difficult to obtain.
Raw Material Joint Venture Revenue $6.7 million in Q2 2025, a decline of approximately $1.6 million compared to Q1 2025, due to economic climate and changes in customer service model mix.
Non-GAAP Gross Margin 8.2% in Q2 2025, compared to negative 6.1% in Q1 2025 and 27.6% in Q2 2024. The improvement from Q1 is attributed to manufacturing process and efficiency improvements, while the year-over-year decline is due to lower revenue and higher costs.
GAAP Gross Margin 8.0% in Q2 2025, compared to negative 6.4% in Q1 2025 and 27.4% in Q2 2024. Similar reasons as non-GAAP gross margin changes.
Non-GAAP Operating Expense $7.6 million in Q2 2025, compared to $8.5 million in Q1 2025 and $8.9 million in Q2 2024. The decrease is due to cost control measures in a difficult climate.
GAAP Operating Expense $8.2 million in Q2 2025, compared to $9.0 million in Q1 2025 and $9.5 million in Q2 2024. Similar reasons as non-GAAP operating expense changes.
Non-GAAP Operating Loss $6.1 million in Q2 2025, compared to $9.6 million in Q1 2025 and $1.2 million in Q2 2024. The improvement from Q1 is due to cost control and gross margin recovery, while the year-over-year decline is due to lower revenue.
GAAP Operating Loss $6.7 million in Q2 2025, compared to $10.3 million in Q1 2025 and $1.9 million in Q2 2024. Similar reasons as non-GAAP operating loss changes.
Non-GAAP Net Loss $6.4 million or $0.15 per share in Q2 2025, compared to $8.2 million or $0.19 per share in Q1 2025 and $0.8 million or $0.02 per share in Q2 2024. The improvement from Q1 is due to cost control and gross margin recovery, while the year-over-year decline is due to lower revenue.
GAAP Net Loss $7.0 million or $0.16 per share in Q2 2025, compared to $8.8 million or $0.20 per share in Q1 2025 and $1.5 million or $0.04 per share in Q2 2024. Similar reasons as non-GAAP net loss changes.
Cash and Cash Equivalents $35.1 million as of June 30, 2025, a decrease of $3.1 million from $38.2 million as of March 31, 2025, due to operating losses and other factors.
Depreciation and Amortization $2.5 million in Q2 2025.
Stock Compensation $0.6 million in Q2 2025.
Net Inventory $80.1 million in Q2 2025, a decrease of approximately $300,000 from Q1 2025, reflecting ongoing efforts to reduce inventory levels.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Indium Phosphide Substrates: Revenue increased in Q2, driven by AI-related demand in China and initial export orders outside China. Revenue expected to grow by 30% or more in Q3.
Gallium Arsenide Substrates: Revenue grew in Q2, with continued growth expected in Q3. Export permits delayed shipments outside China, but permit processing improved in July.
Germanium Substrates: Revenue grew in Q2 due to satellite solar cell applications in China. However, sales are expected to decline in Q3 due to export permit challenges and price sensitivity.
China Data Center Market: Accelerating growth in cloud and data center connectivity, with significant efforts to develop domestic sources for lasers. Indium phosphide sales within China nearly doubled in Q2.
Wireless Market in China: Revenue grew in Q2, with continued growth expected in Q3. Market expansion was measured, focusing on yield and efficiency.
Gross Margin Improvement: Non-GAAP gross margin improved to 8.2% in Q2 from negative 6.1% in Q1. Further improvement expected in Q3.
Operating Expenses: Non-GAAP operating expenses reduced to $7.6 million in Q2 from $8.5 million in Q1. Cost control remains a focus.
Export Permit Process: Delays in export permits for gallium arsenide and indium phosphide impacted revenue. Progress made in July, with additional permits expected in Q3.
Tongmei IPO in China: IPO application remains active, with Tongmei considered a strong candidate despite geopolitical challenges.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Export Restrictions: The company faces delays in obtaining export permits for gallium arsenide and indium phosphide, which has impacted revenue. The permitting process has been slower than expected, particularly for gallium arsenide, causing shipment delays and revenue shortfalls.
Geopolitical Environment: The geopolitical environment, including trade restrictions imposed by the Chinese government, presents near-term headwinds for the business. These restrictions explicitly target materials used for military applications, complicating the export process.
Demand Sluggishness in China: Demand for gallium arsenide in China was sluggish in Q2, with customers taking a cautious approach to ordering and holding inventory. This has negatively impacted revenue growth.
Germanium Substrate Challenges: The germanium substrate business faces challenges due to high raw material costs and difficulties in obtaining export permits for sales outside of China. This has constrained gross margins and is expected to lead to lower sales in the second half of the year.
Economic Climate Impact: The economic climate has negatively impacted the company's raw material joint ventures, leading to a decline in revenue from these operations.
Inventory Management: The company is working to reduce its high inventory levels, which stood at $80.1 million in Q2. This remains a focus area for improvement.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Q3 Revenue: Expected to grow sequentially to be in the range of $19.0 million to $21.0 million. This includes a modest contribution from indium phosphide and gallium arsenide for customers outside of China and revenue for which permits are currently available.
Gross Margin: Expected to improve again in Q3, reaching the low mid- to mid-teens.
Non-GAAP Net Loss: Projected to be in the range of $0.11 to $0.13.
GAAP Net Loss: Projected to be in the range of $0.13 to $0.15.
Indium Phosphide Revenue: Expected to grow by 30% or more in Q3, driven by applications in PON, data center connectivity, and various indium phosphide-based sensors.
Gallium Arsenide Revenue: Expected to grow sequentially in Q3, supported by improved permit processing and growth in wireless business in China.
Germanium Revenue: Expected to decline in Q3 and remain at lower levels through the second half of the year.
Raw Material Business: Expected to remain approximately flat in Q3 compared to the prior quarter.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are there concerns about potential share loss to customers due to delays in the permitting process for indium phosphide?
A:Management acknowledged the delays but emphasized that they continue to receive permits and have a healthy backlog ready to ship. They believe the market is growing too fast to be serviced by just two players and expect the demand for indium phosphide to increase significantly due to advancements in AI and data center applications.
Q:Has the yield issue associated with germanium arsenide for a wireless HPT customer been resolved, and has the business opportunity resumed?
A:Yes, the issue has been resolved, and the business opportunity has resumed. However, the company is taking a conservative approach to improve margins and efficiency before increasing the business portion with the customer.
Q:What is AXTI's perspective on the market growth for optical interconnectivity and indium phosphide substrates?
A:Management stated that the demand for optical interconnectivity and higher-speed transceivers is growing rapidly. They highlighted the need for higher-quality and lower EPD materials, which benefits AXTI. They also noted that the acreage of indium phosphide used in new devices is increasing, and they expect growth rates to be at least as high as previously predicted, if not higher.
Q:What is the composition of the $10 million backlog for indium phosphide and gallium arsenide, and how quickly can it be shipped?
A:More than 50% of the backlog is indium phosphide. Orders are typically turned around in 4 to 6 weeks, and the company has built up work-in-progress inventory. The timing of permit approvals will determine how quickly the backlog can be shipped, but management is confident in seeing an upside to Q3 guidance if permits are received.
Q:Why have gallium arsenide export licenses slowed down, and does this affect the cadence of indium phosphide licenses?
A:Management speculated that the slowdown might be related to China's restrictions on rare earth exports as a negotiating tool. However, they noted that the permit approval process seems to be speeding up again, and they are hopeful for a return to normal cadence for both gallium arsenide and indium phosphide licenses.
Q:Are customers placing advanced orders to build inventory, and could this lead to revenue spikes?
A:Customers have expressed interest in placing large inventory orders once initial urgent orders are delivered. However, the company is not yet at the stage of delivering the first batch of large orders, so this is not an immediate concern.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the reasons behind the slowdown in gallium arsenide export licenses, providing only speculative explanations related to China's rare earth export restrictions. Additionally, they did not provide specific details on the timeline for resolving permitting issues or the exact impact on revenue projections.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AXT
Capital
China AI
China export
Dr Young
EML silicon
EPD
IPO
LLC Research
Non
PON center
PON laser
Research Division
VP Development
application China
approach
axtcom
backlog
center connectivity
center market
climate
customer order
environment China
export permit
focus
gallium indium
interconnect
investor
margin improvement
market China
note
pace
permit indium
permit month
permit process
phosphide China
phosphide substrate
pricing
progress
sale
substrate China
AXTI Transcript
AXT, Inc. (AXTI) Q1 2026 Earnings Call Transcript
Unknown4-30
Despite future growth projections and strategic initiatives like the China subsidiary listing, the company's current financial performance shows a decline in revenue, gross margin, and net income. Risks related to global economic conditions and export permits further exacerbate concerns. The lack of clarity in the Q&A session suggests management's uncertainty, impacting investor confidence. Overall, the negative financial results and operational risks outweigh the optimistic projections, leading to a negative sentiment.
AXT, Inc. (AXTI) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call highlights strong demand for indium phosphide, a record backlog, and plans for capacity expansion, which are positive indicators. Although there are challenges with export permits, management is optimistic about resolving them. The financial performance shows improved margins and reduced losses, and the potential for revenue growth is high. The Q&A session reveals confidence in meeting demand and expanding customer traction. Overall, despite some uncertainties, the company's outlook and strategic initiatives are likely to positively impact the stock price.
AXT, Inc. (AXTI) Q3 2025 Earnings Call Transcript
Positive10-30
The earnings call indicates strong growth in indium phosphide revenue, driven by global demand, particularly outside China. Despite a non-GAAP loss, the company is optimistic about improving gross margins and expanding capacity. The backlog for indium phosphide has more than doubled, and customer interest is high due to product quality. The Q&A session revealed positive analyst sentiment and confidence in future growth. However, the company's cash position has decreased, and some management responses lacked clarity. Overall, the positive growth outlook and strong demand outweigh the financial concerns, suggesting a positive stock price reaction.
AXT, Inc. (AXTI) Q2 2025 Earnings Call Transcript
Unknown7-31
The earnings call summary shows mixed signals: improvements in gross margins and operating expenses are positive, but ongoing losses and cash depletion are concerning. The Q&A reveals potential growth in indium phosphide demand, but uncertainties in export licenses and permitting delays pose risks. The company's optimistic guidance and backlog could boost stock, but lack of clarity on license issues tempers this optimism. The absence of a market cap makes it hard to predict volatility, but overall, the sentiment is balanced, leading to a neutral stock price prediction.
AXTI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
